Literature DB >> 25181955

Difference between true functional haemoglobin and pre-dialysis haemoglobin is associated with plasma volume variation: a multicentre study.

Esteban Siga1, Miguel Fernandez, Mario Galarza, Vito Mesina, Hugo De Palma, Raul Coste.   

Abstract

PURPOSE: Due to the well-known intradialytic haemoglobin (Hb) change, it has been suggested that true functional Hb differs from pre-dialysis Hb. However, mechanisms of this change are not understood properly. We aimed at studying the role of plasma volume variation.
METHODS: This is a multicentre study with two consecutive phases. First, true functional Hb was predicted by Krisper's formula that estimates time-averaged haemoglobin concentration (TAC-Hb) and by the average (Avg-Hb) of Pre-Hb and Post-Hb (n = 346). Erythropoiesis-stimulating agent (ESA) doses were estimated according to the FDA instructions. Second, we investigated the correlations between Hb changes (ΔHb), body weight loss (ΔBW) and relative plasma volume changes (%ΔPV) in subjects with a weight gain higher than 1 kg (n = 208).
RESULTS: First: Avg-Hb and TAC-Hb were similar to each other and higher than midweek Pre-Hb (p < 0. 002). Odds of having an Hb change >1 g/dL were 0.415. Odds were similar in both women and men [odds ratio (OR) 0.923; 95 % confidence interval (CI) 0.591-1.441]. If ESA doses were estimated by TAC-Hb or Avg-Hb instead of Pre-Hb, they should be lower in 40 % of the 346 patients. Second: Mean %ΔPV was -12.1 % (95 % CI -10.72/-13.48), and mean ΔHb was 1.1 g/dL (95 % CI 0.97/1.25). Correlation between ΔHb and %ΔPV was -0.92 (r (2) 0.84) whereas that of ΔHb/ΔBW was just -0.45 (r (2) 0.21; p < 0.000). Prevalence of ΔHb >1 g/dL was independent of ΔBW from 1.4 to 6.3 kg. By contrast, prevalence of ΔHb >1 g/dL in %ΔPV quartiles was clearly linear: 0, 52, 90 and 100 %, respectively.
CONCLUSIONS: Plasma volume variations play a major role in intradialytic Hb change. True functional Hb should be estimated in all patients with a weight gain higher than 1 kg.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25181955     DOI: 10.1007/s11255-014-0774-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?

Authors:  D Vlassopoulos; M Sonikian; V Dardioti; V Hadjiconstantinou
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

Review 2.  Applying the right statistics: analyses of measurement studies.

Authors:  J M Bland; D G Altman
Journal:  Ultrasound Obstet Gynecol       Date:  2003-07       Impact factor: 7.299

3.  Effect of treatment spacing and frequency on three measures of equivalent clearance, including standard Kt/V.

Authors:  John T Daugirdas; James Tattersall
Journal:  Nephrol Dial Transplant       Date:  2009-09-10       Impact factor: 5.992

4.  Evaluation of hemoconcentration from hematocrit measurements.

Authors:  W Van Beaumont
Journal:  J Appl Physiol       Date:  1972-05       Impact factor: 3.531

5.  [Optimizing iron therapy in hemodialysis: a prospective long term clinical study].

Authors:  Esteban Siga; David Aiziczon; Guillermo Díaz
Journal:  Medicina (B Aires)       Date:  2011       Impact factor: 0.653

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

7.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

8.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

9.  Prediction of time-averaged concentration of haemoglobin in haemodialysis patients.

Authors:  Peter Krisper; Franz Quehenberger; Daniel Schneditz; Herwig Holzer; Hans Dietrich Polaschegg
Journal:  Nephrol Dial Transplant       Date:  2003-10       Impact factor: 5.992

10.  Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.

Authors:  Nieves Castillo; Patricia García-García; Antonio Rivero; Alejandro Jiménez-Sosa; Manuel Macía; María Adela Getino; María Luisa Méndez; Javier García-Pérez; Juan F Navarro-González
Journal:  BMC Nephrol       Date:  2012-07-16       Impact factor: 2.388

View more
  1 in total

1.  Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study.

Authors:  Soo Ya Bae; Jae Wan Jeon; Seong Hoon Kim; Chung Hee Baek; Jai Won Jang; Won Seok Yang; Soon Bae Kim; Su-Kil Park; Sang Koo Lee; Hyosang Kim
Journal:  BMC Nephrol       Date:  2019-08-02       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.